Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis.

about

Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis.

Item

http://www.wikidata.org/entity/Q36779759

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Clinical profile and treatment ...... with systemic AL amyloidosis.

@ast

Clinical profile and treatment ...... with systemic AL amyloidosis.

@en

type

Item

label

Clinical profile and treatment ...... with systemic AL amyloidosis.

@ast

Clinical profile and treatment ...... with systemic AL amyloidosis.

@en

prefLabel

Clinical profile and treatment ...... with systemic AL amyloidosis.

@ast

Clinical profile and treatment ...... with systemic AL amyloidosis.

@en

P1476

Clinical profile and treatment ...... with systemic AL amyloidosis.

@en

P2093

Ashutosh D Wechalekar

http://www.w3.org/2001/XMLSchema#string

Christopher Venner

http://www.w3.org/2001/XMLSchema#string

Darren Foard

http://www.w3.org/2001/XMLSchema#string

Julian D Gillmore

http://www.w3.org/2001/XMLSchema#string

Lisa Rannigan

http://www.w3.org/2001/XMLSchema#string

Mark Offer

http://www.w3.org/2001/XMLSchema#string

Philip N Hawkins

http://www.w3.org/2001/XMLSchema#string

Sajitha Sachchithanantham

http://www.w3.org/2001/XMLSchema#string

Shameem A Mahmood

http://www.w3.org/2001/XMLSchema#string

Thirusha Lane

http://www.w3.org/2001/XMLSchema#string

P2860

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.

Dangerous small B-cell clones.

Perspectives in treatment of AL amyloidosis.

Amyloidosis: is a cure possible?

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.

New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.

P304

1469-1476

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2015.128025

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

Helen J Lachmann

P577

2015-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26294730

http://www.w3.org/2001/XMLSchema#string

P932

4825311

http://www.w3.org/2001/XMLSchema#string